Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC
Cancer Letters · 2026-12 · 663 · 218934
DOI: 10.1016/j.canlet.2026.218934 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-12. Verfasst von Xiang-Zheng Gao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Ministry of Education Frontiers Science Center for Precision Oncology, University of Macau, Macao Special Administrative Region …. Die Arbeit nennt 76 Literaturangaben. Gefördert von: Fundo para o Desenvolvimento das Ciencias e da Tecnologia, University of Macau.
Abstract (Originalsprache)
In recent years, significant progress has been made in developing targeted therapy for non-small cell lung cancer (NSCLC). However, these therapies are only applicable to specific NSCLC groups with corresponding gene mutations. Therefore, developing novel targeted therapies to benefit more patients remains an important task. Our prior work demonstrated that LKB1-mutant NSCLC cells are highly susceptible to cell death induced by glucose starvation. In this study, we investigated a novel combinational therapeutic strategy utilizing a sodium-glucose co-transporter-2 (SGLT2) inhibitor canagliflozin and a covalent KRASG12C inhibitor adagrasib, two clinically approved therapeutics, to selectively target LKB1-KRASG12C co-mutated NSCLC. First, we verified the co-occurrence of LKB1 and KRAS mutations in clinical NSCLC cohorts. Second, compared to other SGLT2 inhibitors, canagliflozin induced higher cytotoxicity in LKB1-mutant cells, and SGLT2 knockdown partially attenuated this effect. Mechanistically, the high susceptibility to canagliflozin was associated with impaired activation of AMP-activated protein kinase (AMPK). Furthermore, canagliflozin suppressed mammalian target of rapamycin (mTOR) activity and robustly inhibited cell growth in LKB1-mutant models in vitro. Third, adagrasib exhibited selective cytotoxicity in KRASG12C-mutated NSCLC. Finally, the combination of canagliflozin and adagrasib synergistically reduced cell viability in LKB1-KRASG12C co-mutated H23 and H2122 cells in vitro. Importantly, canagliflozin attenuated the adaptive MAPK signaling rebound induced by adagrasib in vitro. The therapeutic potential of this combination was confirmed in an H2122 nude mouse xenograft model in vivo. Collectively, our findings demonstrate that a combination of canagliflozin and adagrasib suppresses LKB1-KRASG12C co-mutated NSCLC, laying a solid preclinical foundation for developing a new therapeutic strategy for this group of NSCLC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Ministry of Education Frontiers Science Center for Precision Oncology, University of Macau, Macao Special Administrative Region of China.
- Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Zhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China; Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
- Faculty of Medicine, Ministry of Education Frontiers Science Center for Precision Oncology, University of Macau, Macao Special Administrative Region of China. Electronic address: hmshen@um.edu.mo.
Förderung
- Fundo para o Desenvolvimento das Ciencias e da Tecnologia
- University of Macau
Zitieren
APA
Gao, X. Z., Chen, Y., Gao, L., Rong, D., Tang, M., Tang, H., Zhang, Y., Xie, L., Qin, Y., You, S., Wang, J., Lu, G., Ling, Z. Q., & Shen, H. M. (2026). Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC. Cancer Letters, 663, 218934. https://doi.org/10.1016/j.canlet.2026.218934
Vancouver
Gao XZ, Chen Y, Gao L, Rong D, Tang M, Tang H, et al. Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC. Cancer Letters. 2026;663:218934. doi:10.1016/j.canlet.2026.218934
BibTeX
@article{Gao2026,
author = {Gao, Xiang-Zheng and Chen, Yiguan and Gao, Liangliang and Rong, Dade and Tang, Mingzhu and Tang, Haimei and Zhang, Yichi and Xie, Liming and Qin, Yuheng and You, Shuai and Wang, Jingyao and Lu, Guang and Ling, Zhi-Qiang and Shen, Han-Ming},
title = {Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC},
journal = {Cancer Letters},
year = {2026},
volume = {663},
pages = {218934},
doi = {10.1016/j.canlet.2026.218934}
}
EUVIMED